ID   MCF-7 shWDR12-4
AC   CVCL_YJ25
DR   cancercelllines; CVCL_YJ25
DR   Wikidata; Q95986128
RX   CelloPub=CLPUB00550;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Doubling time: 16-18 hours (CelloPub=CLPUB00550).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 8
//
RX   CelloPub=CLPUB00550;
RA   Benhamron S.;
RT   "Validating WDR12 as a potential drug target in triple negative breast
RT   cancer.";
RL   Thesis MSc (2019), University of Toronto, Canada.
//